Cumberland Pharmaceuticals, Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.97-0.03 (-0.60%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5.00
Bid0.00 x
Ask12.00 x 300
Day's Range4.97 - 4.97
52wk Range4.20 - 6.50
1y Target EstN/A
Market Cap80.64M
P/E Ratio (ttm)-497.00
Avg Vol (3m)12,012
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire11 days ago

    Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension

    NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. Portaban™ is an oral formulation of ifetroban and the fourth development candidate in Cumberland's pipeline.

  • Capital Cube17 days ago

    ETF’s with exposure to Cumberland Pharmaceuticals, Inc. : September 8, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswirelast month

    Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support

    NASHVILLE, Tenn., Aug. 23, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.